Edwards Lifesciences Corp Stock Today
| EW Stock | USD 70.46 0.49 0.69% |
PerformanceVery Weak
| Odds Of DistressLow
|
Edwards Lifesciences is selling for under 70.46 as of the 22nd of March 2025; that is 0.69% down since the beginning of the trading day. The stock's lowest day price was 69.82. Edwards Lifesciences has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on November 11, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Edwards Lifesciences Corp's common stock.
Business Domain Health Care Equipment & Services | IPO Date 27th of March 2000 | Category Healthcare | Classification Health Care |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. The company has 587.9 M outstanding shares of which 8.49 M shares are currently sold short in the market by investors with about 1.95 days to cover all shorted shares. More on Edwards Lifesciences Corp
Moving against Edwards Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Edwards Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Michael Mussallem | ||||
| Thematic Ideas | Showing 3 out of 4 themes | ||||
| Old Name | East West Petroleum Corp | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, SP 500 Index, Obamacare Repeal, Healthcare, Macroaxis Picks, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEdwards Lifesciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Edwards Lifesciences' financial leverage. It provides some insight into what part of Edwards Lifesciences' total assets is financed by creditors.
| |||||
Edwards Lifesciences Corp (EW) is traded on New York Stock Exchange in USA. It is located in One Edwards Way, Irvine, CA, United States, 92614 and employs 15,800 people. Edwards Lifesciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a market capitalization of 41.42 B. Edwards Lifesciences Corp is active under Health Care Equipment & Supplies sector as part of Health Care industry. The entity has 587.9 M outstanding shares of which 8.49 M shares are currently sold short in the market by investors with about 1.95 days to cover all shorted shares.
Edwards Lifesciences Corp reports about 769 M in cash with 542.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.81.
Check Edwards Lifesciences Probability Of Bankruptcy
Ownership AllocationEdwards Lifesciences holds a total of 587.9 Million outstanding shares. The majority of Edwards Lifesciences Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Edwards Lifesciences Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Edwards Lifesciences. Please pay attention to any change in the institutional holdings of Edwards Lifesciences Corp as this could imply that something significant has changed or is about to change at the company. On November 11, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Edwards Lifesciences Corp's common stock.
Check Edwards Ownership Details
Edwards Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jennison Associates Llc | 2024-12-31 | 7.5 M | |
| Ninety One Uk Limited | 2024-12-31 | 7.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.1 M | |
| Deutsche Bank Ag | 2024-12-31 | 6.9 M | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 6.5 M | |
| Northern Trust Corp | 2024-12-31 | 6.5 M | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 5.8 M | |
| Wellcome Trust Ltd | 2024-12-31 | 4.8 M | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 4.6 M | |
| Vanguard Group Inc | 2024-12-31 | 69.1 M | |
| Blackrock Inc | 2024-12-31 | 54.5 M |
Edwards Lifesciences Historical Income Statement
Edwards Stock Against Markets
Edwards Lifesciences Corporate Directors
| Paul LaViolette | Independent Director | Profile | |
| Leslie Heisz | Independent Director | Profile | |
| Steven Loranger | Independent Director | Profile | |
| Kieran Gallahue | Independent Director | Profile |
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.